Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072726 | 0.73 | EPHX2 (0.50) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| SCHEMBL11148891 | 0.73 | EPHX2 (0.50) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| Hydrochloric Acid SCHEMBL11156725 | 0.71 | EPHX2 (0.48) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| SCHEMBL6154505 | 0.69 | EPHX2 (0.58) | EPHX2L3MBTL1HSD17B10HSD11B1SIGMAR1 | |
| SCHEMBL3073976 | 0.69 | EPHX2 (1.00) | EPHX2L3MBTL1HSD17B10HSD11B1KMT2A | |
| SCHEMBL3069167 | 0.69 | EPHX2 (0.70) | EPHX2L3MBTL1HSD17B10HSD11B1NPC1 | |
| SCHEMBL12653204 | 0.69 | CA1 (0.48) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| SCHEMBL2297553 | 0.69 | EPHX2 (0.46) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| SCHEMBL1502375 | 0.69 | CA1 (0.48) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 | |
| SCHEMBL12408108 | 0.69 | EPHX2 (0.46) | EPHX2CYP2C9L3MBTL1HSD17B10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110795-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | Hikal Limited (IN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-6376540-B1 | PREVENT NEURODEGENERATIVE DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1021430-A1 | FURAN NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6051571-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6040444-A | Process for preparing furan nitrone compounds | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5942507-A | REAGANTS FOR DETECTION FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998003496-A1 | FURAN NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |